Do you want to read an article? Please log in or register.
Real-world Efficacy, Safety and Heterogenicity of Efficacy of Elexacaftor-Tezacaftor-Ivacaftor in Younger Children (6-11 Years Old) with Cystic Fibrosis
Pulmonary Fibrosis
Related content
Pulmonary Fibrosis
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study
J Cyst Fibros
Goralski JL, Daines C, Pittman JE, Rayment JH, Robinson P, Thursfield R, Stehling F, Ratjen F, Ahluwalia N, Shi P, Lu M, Weinstock TG, Mall MA, VX20-445-112 Study Group
doi: 10.1016/j.jcf.2026.05.014
Further Publications
Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies
Lancet Respir Med
Burgel PR, Da Silva J, Girodon E, Durieu I, Reynaud-Gaubert M, Murris-Espin M, Chiron R, Grenet D, Ramel S, Mely L, Hamidfar R, Douvry B, Houdouin V, Audousset C, Macey J, Mittaine M, Weiss L, Cosson L, Danner-Boucher I, Reix P, Baravalle M, Burnet E, Sermet-Gaudelus I, Martin C, Paillasseur JL, French Cystic Fibrosis Reference Network study group
doi: 10.1016/S2213-2600(25)00190-0
Pulmonary Fibrosis
Real-World Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis: A 24-Month Italian National Registry Study
J Clin Med
Salvatore D, Campagna G, Padoan R, Pepe A, Amato A, Salvatore M
doi: 10.3390/jcm15072699
RECOMMENDED
Pulmonary Fibrosis
Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor on Health-Related Quality of Life in Adults with Cystic Fibrosis: A 12-Month Multicenter Cohort Study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Kharraz R, Tullis E, Sykes J, Ma X, Sandhu A, Gryz Z, Shulman Y, Tam J, Love A, Ratjen F, Rayment JH, Quon BS, Stephenson AL
doi: 10.1016/j.rmed.2026.108827
RECOMMENDED
Pulmonary Fibrosis
Impact of Elexacaftor-Tezacaftor-Ivacaftor on fungal colonisation in children and adolescents with cystic fibrosis
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros
Sitterlé E, Bonnel AS, Roussey-Bihouee T, Blondé A, Ribault M, Wizla N, Bresson C, Persat F, Maubon D, Leroy J, Hassani F, Benhala L, Mounier M, Znaidi S, Ferroni A, Bougnoux ME, Sermet-Gaudelus I, Mycologist and Modul-CF groups
doi: 10.1016/j.jcf.2026.02.012
RECOMMENDED
Pulmonary Fibrosis
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: Results from an open-label extension study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Ann Am Thorac Soc
Chmiel JF, McBennett K, Quon BS, Colombo C, De Wachter E, Fajac I, Mondejar-Lopez P, Polineni D, Robinson P, Sutharsan S, Mall MA, McKone EF, Ramsey B, Taylor-Cousar JL, Tullis E, Suresh NE, Zhang Y, Sosnay P, Jennings M, Barry PJ, 445-110 study group
doi: 10.1093/annalsats/aaoag053
Pulmonary HypertensionFurther Publications
Assessment of efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in an observational cohort study of "aged" people with cystic fibrosis
Ther Adv Respir Dis
Blankenship S, Flueckiger BV, Caleb G, Bailey J, Baker E, Garcia B, Krick S
doi: 10.1177/17534666251410246
RECOMMENDED
Pulmonary FibrosisBronchi
Effect of elexacaftor-tezacaftor-ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study
★ 3
Recommended by
Dr. med. Martin Frey, Faculty Member
Lancet Respir Med
Sermet-Gaudelus I, Letierce A, Berteloot L, Bonnel AS, Chen Y, Makani P, Kelly-Aubert M, Kanoun F, Penalva L, Bouleghem N, Bihouee T, Bui S, Corvol H, Houdouin V, Mittaine M, Tatopoulos A, Weiss L, Wizla N, Kapel N, Bessou A, Tiddens HAWM, Caudri D, Reix P, Marguet C, MODUL-CF study group
doi: 10.1016/S2213-2600(25)00248-6
RECOMMENDED
Pulmonary Fibrosis
Improvement in functional exercise performance and quadriceps muscle strength after two years treatment with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: A prospective observational study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros
Aubriot AS, Song C, Gonçalvès C, Santelé L, Berardis S, Goubau C, Reychler G, Penelle M, Gohy S
doi: 10.1016/j.jcf.2026.07.003